For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 0 | |||
| Cost of revenues | 0 | |||
| Gross profit | 0 | |||
| Gain on lease termination | 0 | |||
| Research and development | 4,156,000 | |||
| General and administrative | 5,163,000 | |||
| Total operating expenses | 9,319,000 | |||
| Loss from operations | -9,319,000 | |||
| Change in fair value of convertible notes | 0 | |||
| Change in fair value to bridge notes derivative liability | 0 | |||
| Change in fair value of contingent consideration | 0 | |||
| Forward Sales Contract Expense | -5,847,000 | |||
| Change in fair value of warrant liabilities | -1,000 | |||
| Interest income | 83,000 | |||
| Interest expense | -27,000 | |||
| Other income, net | 215,000 | |||
| Gains Losses On Extinguishment Of Debt | 800,000 | |||
| Total other expense, net | -4,810,000 | |||
| Loss before income taxes | -14,129,000 | |||
| Benefit (provision) for income taxes | -45,000 | |||
| Net loss | -14,084,000 | |||
| Series a preferred stock dividend | 16,000 | |||
| Net loss attributable to common stockholders | -14,100,000 | |||
| Basic EPS | -2.24 | |||
| Diluted EPS | -2.24 | |||
| Basic Average Shares | 6,307,000 | |||
| Diluted Average Shares | 6,307,000 | |||
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)